Interdisciplinary leadership in cancer care reform Sandra L Wo ng - - PowerPoint PPT Presentation

interdisciplinary leadership in cancer care reform
SMART_READER_LITE
LIVE PREVIEW

Interdisciplinary leadership in cancer care reform Sandra L Wo ng - - PowerPoint PPT Presentation

Interdisciplinary leadership in cancer care reform Sandra L Wo ng , MD MS F ACS F ASCO Pro fe sso r and Chair o f Surg e ry T he Ge ise l Sc ho o l o f Me dic ine at Dartmo uth Se nio r Vic e Pre side nt, Surg ic al Se rvic e L ine I


slide-1
SLIDE 1

Interdisciplinary leadership in cancer care reform

Sandra L Wo ng , MD MS F ACS F ASCO Pro fe sso r and Chair o f Surg e ry T he Ge ise l Sc ho o l o f Me dic ine at Dartmo uth Se nio r Vic e Pre side nt, Surg ic al Se rvic e L ine I nte rim Vic e Pre side nt, Onc o lo g y Se rvic e L ine Dartmo uth-Hitc hc o c k Me dic al Ce nte r

slide-2
SLIDE 2
  • No disclosures relevant to this presentation
slide-3
SLIDE 3

Learning Objectives

  • To review major impact of payment reform
  • n cancer care
  • To connect necessary leadership needs

from all disciplines involved in caring for patients with cancer

slide-4
SLIDE 4

Outline

  • Healthcare reform = payment reform
  • Quality and quality measures
  • Interdisciplinary teams and leadership
slide-5
SLIDE 5

Impetus for healthcare reform

  • Vast numbers of Americans

are uninsured or underinsured

  • Expand access to

healthcare

  • Health costs are high (and

continuing to escalate)

  • Reduce spending
slide-6
SLIDE 6
slide-7
SLIDE 7
slide-8
SLIDE 8
slide-9
SLIDE 9

Belgium Canada England Germany Netherlands Norway US

Inhospital death

51.2% 52.1% 41.7% 38.3% 29.% 44.7% 22.2%

ICU adm (last 180d

  • f life )

17.5% 15.2% 8.2% 10.2% 40.3%

Outpt chemo (last 180d

  • f life)

33.0% 29.1% 28.2% 18.1% 23.7% 38.7%

Per capital hosp exp (last 180d

  • f life)

$15255 $26480 $9216 $24740 $13137 $15849 $26983

Cancer expenditures by country All cancers, age >65

Bekelman JE et al. JAMA 2016;315:272-283

slide-10
SLIDE 10

National spending on cancer care

2010 (2010 billion dollars) 2020 (2010 billion dollars) All sites $124.57 $157.77 Breast 16.50 20.50 Colorectal 14.14 17.41 Lung 12.12 14.73 Prostate 11.85 16.34

Mariotto AB et al. J Natl Cancer Inst 2011;103(2): 117-128.

Projected 27% increase in costs of cancer care in this decade. Assumes current trends of declining incidence and increasing survival.

slide-11
SLIDE 11

Distribution of costs

Cancer services

chemotherapy, RT surgery (inc inpt stay) labs, imaging, hospice,

  • ther inpt stays
  • ther claims

32% 33% 22% 12%

Mariotto AB et al. J Natl Cancer Inst 2011;103(2): 117-128.

slide-12
SLIDE 12

Interdisciplinary

  • ncology care
  • Medical oncology
  • Radiation oncology
  • Surgery
  • Palliative care
  • Medical specialties
  • Primary care
  • Nursing
  • Pharmacy
  • Pathology
  • Radiology
  • Psychiatry
  • PT/OT
  • Social Work
  • Nutrition
  • Scientists (lab, clinical, informatics)
  • Healthcare support staff
  • Policymakers/payers
  • Industry
  • Patients
slide-13
SLIDE 13

Payment reform: Oncology considerations

  • Fundamental implication of reimbursement reform:

Financial risk moves from payers to providers and the care team

  • Oncology is a team sport
  • Decrease variation but keep an eye on innovation and

breakthroughs in treatments

  • Quality must always remain “job one”
slide-14
SLIDE 14

Delivery System Integration Payment Integration

“Usual and customary” DRG / PPS (1984) Episode bundled payments Population spending targets with shared savings ACOs Full capitation

Small MD practices, unrelated hospitals Integrated health delivery systems Fee for service Global budgets

Evolution of healthcare reimbursement

slide-15
SLIDE 15

Delivery System Integration Payment Integration

“Usual and customary” DRG / PPS (1984) Episode bundled payments Population spending targets with shared savings ACOs Full capitation

Small MD practices, unrelated hospitals Integrated health delivery systems Fee for service Global budgets

Evolution of healthcare reimbursement

Clinical pathways Oncology medical home Episode bundled payments Oncology based ACOs

slide-16
SLIDE 16

Delivery System Integration Payment Integration

“Usual and customary” DRG / PPS (1984) Episode bundled payments Population spending targets with shared savings ACOs Full capitation

Small MD practices, unrelated hospitals Integrated health delivery systems FFS Global budgets

Evolution of healthcare reimbursement

Clinical pathways

slide-17
SLIDE 17

Clinical pathways

  • Standardized, evidence-based protocols

for cancer treatment

  • Decreases variation in chemo treatments
  • Discourages “buy and bill” model for

chemotherapy

  • Payment schema

– Per member per month case management fee – Could include supplemental payments for adherence or achievement of quality benchmarks

slide-18
SLIDE 18

Delivery System Integration Payment Integration

“Usual and customary” DRG / PPS (1984) Episode bundled payments Population spending targets with shared savings ACOs Full capitation

Small MD practices, unrelated hospitals Integrated health delivery systems FFS Global budgets

Evolution of healthcare reimbursement

Oncology medical home

slide-19
SLIDE 19

Oncology Medical Home

  • Focuses on patient-centered care

management

  • Practice level approach to promote care

coordination

  • Some evidence to suggest lower ED visits,

hospital admissions?

  • Payment schema

– Per member per month case management fee to support care coordination across the care team

slide-20
SLIDE 20

Delivery System Integration Payment Integration

“Usual and customary” DRG / PPS (1984) Episode bundled payments Population spending targets with shared savings ACOs Full capitation

Small MD practices, unrelated hospitals Integrated health delivery systems FFS Global budgets

Evolution of healthcare reimbursement

Episode bundled payments

slide-21
SLIDE 21

Episode-based bundled payments

  • Set payment based on specific set of

services over a predetermined period

  • There is a lot of variation in payments
  • Providers have flexibility (and incentive) to

redirect resources to cost-effective services

slide-22
SLIDE 22

Bundled payments

  • Variation is specific to the disease site,

across specialties

  • Quality is an important driver of variation

– Complications are costly

  • Beware of risks associated with very large
  • r small bundles
slide-23
SLIDE 23

Abdelsattar et al. J Oncol Pract 2015

Variation in payments for colorectal cancer

slide-24
SLIDE 24

ACOs & Shared savings plans

  • ACO: Group of caregivers that agree to share

responsibility and accountability for care of a population of patients

  • Accountability

– Population‐based spending – Defined array of quality metrics (to discourage skimping on care)

  • Current adoption: approx 400 health systems

– Pioneer ACOs (more risk, more reward, more hassle) – Medicare Shared Savings Programs

slide-25
SLIDE 25

Success with bundled payments

  • Understand comparative efficiency across

specialties (and thus best opportunities for improvement)

  • Minimize utilization of discretionary services
  • Optimize quality
  • Complications can be costly
  • Avoid readmissions
slide-26
SLIDE 26

Variation in payment for colorectal cancer

Abdelsattar et al. J Oncol Pract 2015

slide-27
SLIDE 27

Variation in payment for colorectal cancer

Abdelsattar et al. J Oncol Pract 2015

slide-28
SLIDE 28

Delivery System Integration Payment Integration

“Usual and customary” DRG / PPS (1984) Episode bundled payments Population spending targets with shared savings ACOs Full capitation

Small MD practices, unrelated hospitals Integrated health delivery systems FFS Global budgets

Evolution of healthcare reimbursement

Oncology based ACOs

slide-29
SLIDE 29

Oncology-based ACOs

  • Typically population-based patient cohort

so excellent care coordination across systems is necessary

  • Accountability for costs of care in

exchange for shared savings

  • Payments are tied to overall costs and

performance on quality measures

  • Beware of risks associated with one- and

two-sided risk models

slide-30
SLIDE 30

Value = quality / cost

Effective Efficient Safe quantity * price Timely Patient-centered Equitable

Source: Crossing the Quality Chasm Institute of Medicine, 2001

slide-31
SLIDE 31

Why measure?

  • To improve care
  • The short history of hospital quality measurement

– Codman’s “end results” cards (1910’s) – Developed M&M conferences – “Forerunner” of The Joint Commission

  • Today, it’s not whether to measure but how to do it better

– Less resistance – Better data quality – Increasing transparency about the data – Still needs to be led by those of us who provide care

slide-32
SLIDE 32

Targeting what to measure

  • Characteristics of a good quality measure

– Solid evidence base supports that the metric leads to an improved

  • utcome

– The measure actually captures whether care was delivered – The process is in the direct causal pathway of the outcome – No unintended consequences as a result of the metric

Chassin et al. N Engl J Med 2010;363:683‐688

slide-33
SLIDE 33

Targeting what to measure

  • Characteristics of a good quality measure

– Solid evidence base supports that the metric leads to an improved

  • utcome
slide-34
SLIDE 34

Targeting what to measure

  • Characteristics of a good quality measure

– Solid evidence base supports that the metric leads to an improved

  • utcome

– The measure actually captures whether care was delivered

slide-35
SLIDE 35

Smoking cessation

Defined interventions:

  • Counseling

– Individual – Group (proctored, peer) – Telephone

  • Behavioral therapy
  • Longitudinal programs

– Person‐to‐person contact – eHealth programs

  • Pharmaceutical help

– Nicotine replacement – Other Rx

VS “You should stop smoking”

slide-36
SLIDE 36

Targeting what to measure

  • Characteristics of a good quality measure

– Solid evidence base supports that the metric leads to an improved

  • utcome

– The measure actually captures whether care was delivered – The process is in the direct causal pathway of the outcome

slide-37
SLIDE 37

Comparison between patient satisfaction and outcomes

Wright et al. JNCI J Natl Cancer Inst 2015;107

slide-38
SLIDE 38

Targeting what to measure

  • Characteristics of a good quality measure

– Solid evidence base supports that the metric leads to an improved

  • utcome

– The measure actually captures whether care was delivered – The process is in the direct causal pathway of the outcome – No unintended consequences as a result of the metric

slide-39
SLIDE 39

N=1193 patients with stage IV lung or colorectal cancer

  • Alive 4 months after treatment
  • Queried about expectations about

chemotherapy treatment

  • 69% (lung cancer) and 81%

(colorectal cancer) did not understand that treatment was not at all likely to cure

  • Patients tended to be “overly
  • ptimistic” especially those who gave

higher scores for physician communication Weeks et al. NEJM 2012;367:1616

slide-40
SLIDE 40

Lessons from measurement

  • There is an effect of measurement itself
  • Measurement alone is not enough
  • Sometimes we measure incorrectly
  • Measurement must be rigorous
slide-41
SLIDE 41

Lessons from measurement

  • There is an effect of measurement itself

– Hawthorne Effect

slide-42
SLIDE 42

Lessons from measurement

  • There is an effect of measurement itself
  • Measurement alone is not enough

– Measurement detects variation – Data must be shared and understood – QI tools are needed

slide-43
SLIDE 43

Dartmouth-Hitchcock Medical Center Fletcher Allen Health Care Eastern Maine Medical Center Maine Medical Center Catholic Medical Center

The Northern New England Cardiovascular Disease Study Group, 1987‐

slide-44
SLIDE 44
slide-45
SLIDE 45

CABG mortality in Northern New England: The impact of the NNE collaborative

1 2 3 4 5 6

1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000

Year Mortality Rate (%)

Clinicians learning from data and each other Data feedback to surgeons

Slide courtesy of J. Birkmeyer

slide-46
SLIDE 46

Jha and Epstein. Health Aff 2006;25(3):844‐855

NY State’s Public Reporting Program for Cardiac Surgery

slide-47
SLIDE 47

Lessons from measurement

  • There is an effect of measurement itself
  • Measurement alone is not enough
  • Sometimes we measure incorrectly
slide-48
SLIDE 48

Why is staging important?

  • Guides treatment
  • Informs prognosis
  • Measurement and evaluation

– Common terminology between providers – Classification

slide-49
SLIDE 49
slide-50
SLIDE 50
slide-51
SLIDE 51

Harms et al. Ann Surg Oncol 2016

slide-52
SLIDE 52

New 8th edition AJCC staging system

Clinical Staging– N category cNx, regional lymph nodes cannot be clinically assessed (e.g. previously removed for another reason, body habitus) cN0, no regional lymph node metastasis by clinical or radiological evaluation cN1, clinically detected regional nodal metastasis cN2, in‐transit metastasis without lymph node metastasis cN3, in‐transit metastasis with lymph node metastasis Pathological Staging– N category pNx, regional lymph nodes cannot be assessed (e.g. previously removed for another reason) or not removed for pathological evaluation pN0, no regional lymph node metastasis detected on pathological evaluation pN1a(sn), clinically occult nodal metastasis identified

  • nly by sentinel lymph node biopsy

pN1a, clinically occult regional lymph node metastasis following lymph node dissection pN1b, clinically or radiologically detected regional lymph node metastasis, pathologically confirmed pN2, in‐transit metastasis without lymph node metastasis pN3, in‐transit metastasis with lymph node metastasis

Harms et al. Ann Surg Oncol 2016

slide-53
SLIDE 53

Lessons from measurement

  • There is an effect of measurement itself
  • Measurement alone is not enough
  • Sometimes we measure incorrectly
  • Measurement must be rigorous

– Benchmarking requires standardization of data collection

slide-54
SLIDE 54

What constitutes a true surgical site infection?

Taylor et al. J Oncol Pract 2016

slide-55
SLIDE 55

There’s a lot of hard work to be done

slide-56
SLIDE 56

Interdisciplinary

  • ncology care
  • Medical oncology
  • Radiation oncology
  • Surgery
  • Palliative care
  • Medical specialties
  • Primary care
  • Nursing
  • Pharmacy
  • Pathology
  • Radiology
  • Psychiatry
  • PT/OT
  • Social Work
  • Nutrition
  • Scientists (lab, clinical, informatics)
  • Healthcare support staff
  • Policymakers/payers
  • Industry
  • Patients
slide-57
SLIDE 57

Interdisciplinary

  • ncology care
  • The future may not be
  • ur tumor boards and

site-specific teams as we know them

  • “Next gen” care

coordination will challenge our ability to truly integrate

slide-58
SLIDE 58

Team Readiness

  • Integration
  • Aligning incentives for cancer programs

(populations, hospitals, all members of the care team across the continuum of care)

  • Systems‐oriented leaders in oncology
slide-59
SLIDE 59

What will it take?

  • Psychological safety and familiarity assure high‐quality

communication

– Medical team training  “speak up” – Proven increase in patient safety – More nimble with implementation of new programs

  • Challenges

– Hierarchy‐ and continuum‐related status differences – Geographic dispersion – Alignment with organizational culture

Adapted from Jain et al. J Oncol Pract 2016

slide-60
SLIDE 60

Vogel et al. J Oncol Pract 2016

slide-61
SLIDE 61
slide-62
SLIDE 62
slide-63
SLIDE 63

Conclusions

  • Payment reform is an incentive and
  • pportunity for quality improvement
  • Effective coordination of cancer care

comes from interdisciplinary teamwork

slide-64
SLIDE 64

Thank you

Sandra.L.Wong@hitchcock.org